Probe: Diabetes drug builder kept risks quiet
New York, N.Y. — A Senate inform pronounced Saturday which drug builder Glaxo-SmithKline knew of probable heart conflict risks scored equally to Avandia, the diabetes drug, years prior to such justification became public.

Read some-more upon The Des Moines Register